Québec, QUEBEC, December 19, 2025 – Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD) (OTCQB: DVHGF), a biopharmaceutical Company specializing in the development of prescription drugs targeting inflammatory diseases today announced the grant of Stock Options.

Grant of Stock Options

The Company announces that the Board of Directors has approved the granting of 2,948,056 stock options to directors and a consultant of the Company. Of the options, 2,798,056 were granted to directors of the Company. The Options are exercisable (‘‘vested’’) at a price of $0.18 on grant date, for a period of 10 years following the grant date.

The Board of Directors has also approved the granting of 385,950 stock options to employees of the Company as part of their performance bonus and as retainer. In addition, 100,000 stock options were granted to a research and development consultant.These options are vested on the following schedule: 25% on grant date and then 25% per year for 3 years.

About Thykamine™

Thykamine™, the first pharmaceutical product issued from Devonian’s SUPREX™ platform, is a highly innovative product for the prevention and treatment of health conditions related to inflammation and oxidative stress including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune disorders. The anti-inflammatory, anti-oxidative and immunomodulatory properties of Thykamine™ have been demonstrated by a considerable number of in vitro and in vivo studies as well as in a Phase IIa clinical study in patients with mild-to-moderate distal ulcerative colitis and in a large Phase II study in adult patients with mild-to-moderate Atopic Dermatitis. Both Thykamine™ and SUPREX™ platform are covered by patents issued in several North American, European and Asian countries.

About Devonian

Devonian Health Group Inc. is a clinical stage pharmaceutical company specializing in the development of drugs for various auto-immune inflammatory conditions with novel therapeutic approaches to targeting unmet medical needs. Devonian’s core strategy is to develop prescription drugs for the treatment of inflammatory autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian’s focus is further supported by a U.S. Food and Drug Administration set of regulatory guidelines favoring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines.

Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian also owns a commercialization subsidiary, Altius, focused on selling prescription pharmaceutical products in Canada, under a license from brand name pharmaceutical companies.

Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Quebec, Canada where it owns a state-of-the art extraction facility with full traceability ‘from the seed to the pill’. Devonian is traded publicly on the TSX Venture Exchange (the “Exchange”) (TSXV: GSD) and on OTCQB Venture Market (OTCQB: DVHGF).

For more information, visit www.groupedevonian.com.

Cautionary Note Regarding Forward-Looking Statements

All statements, other than statements of historical fact, contained in this press release including, but not limited to those relating, the impact of proposed optimizations at the Companys’ projects, global liquidity and credit availability on the timing of cash flows and the values of assets and liabilities based on projected future conditions, changes in accounting policies, the impact of inflation, the PCT patents for Thykamine^TM might not be granted, and, generally, the above “About Devonian” paragraphs, which essentially describes the Company’s outlook, constitute “forward-looking information” or “forward-looking statements” within the meaning of certain securities laws, and are based on expectations, estimates and projections as of the time of this press release.

Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect. Many of these uncertainties and contingencies can directly or indirectly affect, and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that these assumptions will prove to be correct and there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections and other forward-looking statements will not be achieved or that assumptions do not reflect future experience. Forward-looking statements are provided for the purpose of providing information about management’s expectations and plans relating to the future. Readers are cautioned not to place undue reliance on these forward-looking statements as a number of important risk factors and future events could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates, assumptions and intentions expressed in such forward-looking statements. All the forward-looking statements made in this press release are qualified by these cautionary statements and those made in our other filings with the applicable securities regulators of Canada. The Company refuses any intention or obligation to update or revise any forward-looking statements or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law.

Neither the Exchange nor its Regulation Services Provider (as that term is defined in policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

CONTACT:
Devonian Health Group Inc.
Dr. Andre Boulet, Chairman and Chief Executive Officer
Telephone: 1 (450) 979-2916
E-mail: investors@groupedevonian.com

The post Devonian Health Group Announces Grant of Stock Options appeared first on DEVONIAN HEALTH GROUP INC..

• Company continues preclinical studies for Thykamine™ in MASH and Fibrosis, furthering the understanding of Thykamine™’s mechanism of action.
• Thykamine™: A New Player in the Field of Anti-Inflammatory Drugs published in the peer reviewed journal, Biomedicines.
• Design for Thykamine™ Phase 2/3 clinical study in pediatric Atopic Dermatitis is complete based on the positive results of the phase 2 in an adult population.
• Thykamine™ radiodermatitis pivotal clinical study in the process of being initiated.
• First quarter gross margin on distribution revenues of $0.5 million
• First quarter net loss of $1.6 million dollars, ($0.01) per share
• Private placements completed with gross proceeds of $2.7 million
• Cash as of October 31, 2025 of $6.6 million; Company remains debt free

Québec, QUEBEC, December 12, 2025 – Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), today announced operating and financial results for its first quarter ended on October 31, 2025.

Management Comments

‘‘We are very pleased with the continued momentum across both our therapeutic and commercial activities this quarter. Thykamine™’s progress in preclinical MASH and fibrosis strengthens its profile as a promising first-in-class anti-inflammatory candidate, while the readiness of our Phase 2/3 pediatric atopic dermatitis study marks an important milestone toward addressing a significant unmet medical need. Our gross margin performance, combined with the successful completion of $2.7 million in private placements, reflects growing confidence in our strategy and in the long-term value of our pipeline’’ said Dr Andre Boulet, PhD, Chief Executive Officer of Devonian.

Business Highlights

• The Company finalized the protocol for a 12-week, multicenter, randomized, double-blind, vehicle-controlled, Phase 2/3 clinical study investigating the safety and efficacy of two strengths. (0.05% and 0.1%) of PUR 0110 (Thykamine™) Cream applied twice daily to pediatric patients (3 months to 17 years of age) with mild to moderate atopic dermatitis (the “Pediatric AD clinical study”). The study is ready to be initiated following approval by regulatory agencies.
• The Company is preparing its pivotal clinical study of Thykamine™ for radiodermatitis. It will be a double-blind, randomized, Glaxal-based, controlled multicenter study in patients with breast cancer.
• Preclinical studies are ongoing to highlight the potential of Thykamine™ to be used in the treatment of MASH.
• Further preclinical studies initiated to elucidate the potential use of Thykamine™ as an anti-fibrotic agent.
• On November 26, 2025, subsequent to the close of the quarter, the Company announced the appointment of Mr. Pierre Labbé as new board member following the resignation from the board of directors of Mr. Jean Forcione on September 30, 2025.

Financial Highlights

Financing

• During the quarter ended October 31, 2025, the Company successfully completed $2.7 million of financing with issuance of units (common shares and warrants) through private placements, strengthening its liquidity. Cash and cash equivalents of $6.6 million at the end of the period, modestly lower than the $7.0 million reported as of July 31, 2025. The Company is debt free.

Distribution revenues

• Distribution revenues for the three-month period ended October 31, 2025 were $1.05 million, an 83% decrease from $6.12 million in the comparable period, reflecting the expiry of the Dexlansoprazole distribution agreement in April 2025.

Net loss

• The Company reported a net loss during the quarter of $1.6 million as compared to a net loss of $0.6 million for the same period in 2024. The comparative period increases in net loss of nearly $1 million relates to the distribution revenues decline which reduced the gross margin by $1.5 million. This reduction was partially offset by a $0.5 million savings in selling and administrative as well as financial expenses.

Cash flows

• The Company used $2.3 million in operating activities cash flows, compared with generating $2.6 million in the same period last year. The $4.9 million decrease in operating cash flows is mainly due to the net change in non-cash working capital items for an amount of nearly $3.5 million related to the payments of accounts payable, as well as the $1.4 million higher comparative net loss net of items not affecting cash.

To consult the Interim Consolidated Financial Statements for the three-month periods ended October 31, 2025 and 2024, please click on the following link: https://groupedevonian.com/investor-center/financial-reports/ or see the Company profile on SEDAR+.

About Thykamine™

Thykamine™, the first pharmaceutical product issued from Devonian’s SUPREX™ platform, is a highly innovative product for the prevention and treatment of health conditions related to inflammation and oxidative stress including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune disorders. The anti-inflammatory, anti-oxidative and immunomodulatory properties of Thykamine™ have been demonstrated by a considerable number of in vitro and in vivo studies as well as in a Phase 2a clinical study in patients with mild-to-moderate distal ulcerative colitis and in a large Phase 2 study in adult patients with mild-to-moderate Atopic Dermatitis. Both Thykamine™ and SUPREX™ platform are covered by patents issued in several North American, European and Asian countries.

About Devonian

Devonian Health Group Inc. is a clinical stage pharmaceutical company specializing in the development of drugs for various auto-immune inflammatory conditions with novel therapeutic approaches to targeting unmet medical needs. Devonian’s core strategy is to develop prescription drugs for the treatment of inflammatory autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian’s focus is further supported by a U.S. Food and Drug Administration set of regulatory guidelines favoring drug development pathway for prescription botanical drug products.

Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian also owns a commercialization subsidiary, Altius, focused on selling prescription pharmaceutical products in Canada, under a license from brand name pharmaceutical companies.

Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Québec (Quebec) Canada where it owns a state-of-the art extraction facility. Devonian is traded publicly on the TSX Venture Exchange (the “Exchange”) (TSXV: GSD) and on OTCQB Venture Market (OTCQB: DVHGF).

For more information, visit www.groupedevonian.com.

Cautionary Note Regarding Forward-Looking Statements

All statements, other than statements of historical fact, contained in this press release including, but not limited to those relating, the impact of proposed optimizations at the Corporations’ projects, global liquidity and credit availability on the timing of cash flows and the values of assets and liabilities based on projected future conditions, changes in accounting policies, the impact of inflation, the PCT patents for Thykamine^TM might not be granted, and, generally, the above “About Devonian” paragraphs, which essentially describes the Corporation’s outlook, constitute “forward-looking information” or “forward-looking statements” within the meaning of certain securities laws, and are based on expectations, estimates and projections as of the time of this press release.

Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Corporation as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect. Many of these uncertainties and contingencies can directly or indirectly affect, and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that these assumptions will prove to be correct and there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections and other forward-looking statements will not be achieved or that assumptions do not reflect future experience. Forward-looking statements are provided for the purpose of providing information about management’s expectations and plans relating to the future. Readers are cautioned not to place undue reliance on these forward-looking statements as a number of important risk factors and future events could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates, assumptions and intentions expressed in such forward-looking statements. All the forward-looking statements made in this press release are qualified by these cautionary statements and those made in our other filings with the applicable securities regulators of Canada. The Corporation refuses any intention or obligation to update or revise any forward-looking statements or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law.

Neither the Exchange nor its Regulation Services Provider (as that term is defined in policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

CONTACT :

Devonian Health Group inc.
Dr. André Boulet, PhD, Chairman and Chief Executive Officer
Telephone : 1 450 979-2916
E-mail : investors@groupedevonian.com

The post Devonian Health Group Reports Financial Results of its First Quarter Ended on October 31, 2025 and Provides Corporate Update appeared first on DEVONIAN HEALTH GROUP INC..

QUÉBEC, Dec. 4, 2025 – Devonian Health Group Inc. (“Devonian” or the “Corporation“) (TSXV: GSD) (OTCQB: DVHGF), a biopharmaceutical corporation specializing in the development of prescription drugs targeting fibroinflammatory diseases, is pleased to announce the publication of a peer-reviewed article in Biomedicines titled “Thykamine™: A New Player in the Field of Anti-Inflammatory Drugs.” The study presents notable evidence supporting the potent multi-target anti-inflammatory properties of Thykamine™, the Corporation’s lead pharmaceutical candidate.

The article, published in peer-reviewed BioMedicines Journal and titled, ”Thykamine™: A New Player in the Field of Anti-Inflammatory Drugs”, is now available online at: https://www.mdpi.com/2227-9059/13/12/2938. It was co-authored by Dr. Charles Lynde, Associate Professor in the Department of Medicine at the University of Toronto; Professor (Pr) Louis Flamand, Department of Microbiology, Infectious Disease and Immunology, Faculty of Medicine, Université Laval; Vincent McCarty and Dr. John Sampalis, Department of Surgery, McGill University, Montreal, Canada.

In this study, researchers compared the effect of Thykamine™ with six widely prescribed anti-inflammatory drugs (including corticosteroids such as betamethasone, clobetasol, hydrocortisone, prednisone; and non-steroidal therapies such as crisaborole and pimecrolimus). Using an in vitro model of immune-activated cells, they measured secretion levels of major chemokines (inflammatory markers) — MCP-1, MIP-1α, MIP-1β and RANTES — after inflammatory stimulation. Thykamine™ inhibited secretion of MCP-1, MIP-1α, and MIP-1β with significantly greater potency than all comparators and suppressed RANTES secretion to a degree comparable or superior to most agents tested.

Importantly, these effects were observed at lower concentrations and without detectable cytotoxicity, suggesting a notably favorable safety profile. This unique combination of multi-target efficacy and cellular tolerability positions Thykamine™ as a strong candidate for next-generation therapeutic development targeting chronic inflammatory conditions.

A New Paradigm for Inflammation Management

Chronic inflammation contributes to a wide spectrum of medical conditions, ranging from dermatological diseases such as atopic dermatitis (eczema) to gastrointestinal disorders and systemic autoimmune pathologies. When left unresolved, persistent inflammation can also drive the development of fibrosis—progressive tissue scarring that disrupts normal organ architecture and function. Over time, this fibrotic remodeling can lead to irreversible organ damage and failure, representing one of the most serious long-term consequences of chronic inflammatory diseases.

The findings published in Biomedicines reinforce Thykamine™’s potential to address this unmet medical need by offering a plant-derived, multi-mechanistic alternative capable of modulating inflammation across several biologically relevant pathways —potentially impacting both inflammatory and fibrotic processes.

”The results with Thykamine™ are very encouraging. For too long, patients have had to choose between effectiveness and tolerability. Thykamine™ offers a real possibility of bridging that gap — combining potent suppression of harmful inflammation with a gentler safety profile. We believe this could represent a paradigm shift in how we manage chronic inflammatory and autoimmune conditions.” said Dr. André P. Boulet, PhD, Chairman & CEO of Devonian.

About Thykamine™

Thykamine™, the first pharmaceutical product issued from Devonian’s SUPREX™ platform, is a highly innovative product for the prevention and treatment of health conditions related to inflammation and oxidative stress including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune disorders. The anti-inflammatory, anti-oxidative and immunomodulatory properties of Thykamine™ have been demonstrated by a considerable number of in vitro and in vivo studies as well as in a Phase IIa clinical study in patients with mild-to-moderate distal ulcerative colitis and in a large Phase II study in adult patients with mild-to-moderate Atopic Dermatitis. Both Thykamine™ and SUPREX™ platform are covered by patents issued in several North American, European and Asian countries.

About Devonian

Devonian Health Group Inc. is a clinical stage pharmaceutical company specializing in the development of drugs for various auto-immune inflammatory conditions with novel therapeutic approaches to targeting unmet medical needs. Devonian’s core strategy is to develop prescription drugs for the treatment of inflammatory autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian’s focus is further supported by a U.S. Food and Drug Administration set of regulatory guidelines favoring drug development pathway for prescription botanical drug products. Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings.

Devonian also owns a commercialization subsidiary, Altius, focused on selling prescription pharmaceutical products in Canada, under a license from brand name pharmaceutical companies. Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Québec (Quebec) Canada where it owns a state-of-the art extraction facility.

Devonian is traded publicly on the TSX Venture Exchange (the “Exchange“) (TSXV: GSD) and on OTCQB Venture Market (OTCQB: DVHGF).

For more information, visit www.groupedevonian.com.

Cautionary Note Regarding Forward-Looking Statements

All statements, other than statements of historical fact, contained in this press release including, but not limited to those relating, the impact of proposed optimizations at the Corporations’ projects, global liquidity and credit availability on the timing of cash flows and the values of assets and liabilities based on projected future conditions, changes in accounting policies, the impact of inflation, the PCT patents for Thykamine^TM might not be granted, and, generally, the above “About Devonian” paragraphs, which essentially describes the Corporation’s outlook, constitute “forward-looking information” or “forward-looking statements” within the meaning of certain securities laws, and are based on expectations, estimates and projections as of the time of this press release.

Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Corporation as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect. Many of these uncertainties and contingencies can directly or indirectly affect, and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that these assumptions will prove to be correct and there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections and other forward-looking statements will not be achieved or that assumptions do not reflect future experience. Forward-looking statements are provided for the purpose of providing information about management’s expectations and plans relating to the future. Readers are cautioned not to place undue reliance on these forward-looking statements as a number of important risk factors and future events could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates, assumptions and intentions expressed in such forward-looking statements. All the forward-looking statements made in this press release are qualified by these cautionary statements and those made in our other filings with the applicable securities regulators of Canada. The Corporation refuses any intention or obligation to update or revise any forward-looking statements or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law.

Neither the Exchange nor its Regulation Services Provider (as that term is defined in policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

CONTACT :

Devonian Health Group inc.
Dr. André Boulet, PhD, Chairman and Chief Executive Officer
Telephone : 1 450 979-2916
E-mail : investors@groupedevonian.com

The post Devonian Health Group Announces Publication of Landmark Study Highlighting Thykamine™ as a Promising New Anti-Inflammatory Agent appeared first on DEVONIAN HEALTH GROUP INC..

QUÉBEC, Nov. 26, 2025 /CNW/ – Devonian Health Group Inc. (“Devonian” or the “Corporation“) (TSXV: GSD) (OTCQB: DVHGF), a biopharmaceutical corporation specializing in the development of prescription drugs targeting inflammatory diseases today announced financial results for its fourth quarter and fiscal year ended July 31, 2025.

CONTACT:

The post Devonian Health Group Reports its Fourth Quarter and Annual 2025 Financial Results and Appointment of a New Board Member appeared first on DEVONIAN HEALTH GROUP INC..

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

QUEBEC, Oct. 22, 2025 – Devonian Health Group Inc. (“Devonian” or the “Corporation“) (TSXV: GSD) (OTCQB: DVHGF), a biopharmaceutical corporation specializing in the development of prescription drugs targeting inflammatory diseases today announced that Dr. André Boulet, PhD, Chairman and Chief Executive Officer, will present at the ThinkEquity Conference on Thursday, October 30, 2025.

The event will bring together leading institutional investors, analysts, and growth-oriented companies for presentations and networking opportunities.

Event Details:

• Conference: The ThinkEquity Conference
• Location: Mandarin Oriental, 80 Columbus Circle, New York City
• Date: October 30, 2025
• Presentation: 12:30 pm at the Lotus Suite West

Institutional investors interested in meeting with Devonian Health Group’s management are encouraged to contact and to register on the conference website to request a meeting.

Non-brokered Private Placement

The Company also announces that it has closed a non-brokered private placement for aggregate gross proceeds of $334,500.33 (the “Offering“). The Offering consisted of the issuance of 1,967,649 units of the Corporation (the “Units“) at a price of $0.17 per Unit. Each Unit consists of one common share of the Corporation (a “Share“) and one Share purchase warrant (a “Warrant“). Each Warrant entitles the holder thereof to purchase one Share at an exercise price of $0.17 per Share for a period of 24 months from the date of issuance thereof.

The proceeds of the Offering will primarily be used to finance working capital related to the Corporation’s corporate overhead and research and development activities.

A total of $14,166.68 cash finder’s fees were paid in connection with this Offering. The Shares and the Warrants issued pursuant to this Offering are subject to a restricted hold period of four months and one day, ending on February 23, 2026, under applicable Canadian securities laws. The Offering remains subject to the final approval of the TSX Venture Exchange.

About Devonian

Devonian Health Group Inc. is a biopharmaceutical company developing innovative prescription drugs. The Company’s core business is the development of prescription drugs targeting inflammatory diseases.

For more information, please visit www.groupedevonian.com

Cautionary Note Regarding Forward-Looking Statements

All statements, other than statements of historical fact, contained in this press release including, but not limited to those relating to the intended use of proceeds, the final approval of the TSX Venture Exchange in connection with the Offering and generally, the above “About Devonian” paragraph, which essentially describes the Corporation’s outlook, constitute “forward-looking information” or “forward-looking statements” within the meaning of certain securities laws, and are based on expectations, estimates and projections as of the time of this press release.

Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Corporation as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect. Many of these uncertainties and contingencies can directly or indirectly affect, and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that these assumptions will prove to be correct and there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections and other forward-looking statements will not be achieved or that assumptions do not reflect future experience. Forward-looking statements are provided for the purpose of providing information about management’s expectations and plans relating to the future. Readers are cautioned not to place undue reliance on these forward-looking statements as a number of important risk factors and future events could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates, assumptions and intentions expressed in such forward-looking statements. All of the forward-looking statements made in this press release are qualified by these cautionary statements and those made in our other filings with the applicable securities regulators of Canada. The Corporation disclaims any intention or obligation to update or revise any forward-looking statements or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) and may not be offered or sold to, or for the account or benefit of, persons in the United States or U.S. persons absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws. “United States” and “U.S. person” are as defined in Regulation S under the U.S. Securities Act.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CONTACT:

Dr. André P. Boulet, PhD
Chairman and Chief Executive Officer
Devonian Health Group inc.
Telephone: (450) 979-2916
E-mail: investors@groupedevonian.com

The post Devonian Health Group Inc. announces its participation to the ThinkEquity Conference in New York and closing of a Non-Brokered Private Placement of Units appeared first on DEVONIAN HEALTH GROUP INC..

Devonian Provides Corporate Update and Additional Information Regarding its Previously Announced Private Placement

QUEBEC, August 22, 2025 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to inflammatory diseases, provides today corporate update:

Thykamine™: Pipeline Advances on Multiple Fronts

On the manufacturing front, batch-to-batch consistency of Thykamine™ has been validated through advanced analytical techniques, including High Performance Liquid Chromatography–Mass Spectrometry (HPLC-MS) and Nuclear Magnetic Resonance (NMR). These results highlight the robust quality and reliability of our production process for this first-in-class therapeutic.

Pre-clinical programs are progressing to further demonstrate Thykamine™’s unique dual action on both inflammation and fibrosis pathways. Current studies in Metabolic Associated Steatohepatitis (MASH) and pulmonary fibrosis models are designed to confirm its potential as a broadly applicable anti-inflammatory and anti-fibrotic drug. Data readouts are expected in fall 2025 and are anticipated to support expansion into multiple high-value indications.

In parallel, the company is advancing development of oral formulations (liquid and capsule) to unlock additional opportunities in Ulcerative Colitis and other diseases where oral delivery is preferred. This strategic diversification broadens Thykamine™’s market reach and strengthens its long-term commercial potential.

Finally, a U.S. survey of dermatologists confirmed the acceptance of Thykamine™ cream in pediatric patients with mild-to-moderate atopic dermatitis, further supporting its clinical relevance and commercial potential. This positive outcome validates Devonian’s strategy to target this underserved population and further reinforces the commercial viability of Thykamine™ across multiple therapeutic areas.

Altius Healthcare LP

As announced on February 7, 2025, the distribution license for Dexlansoprazole was not renewed and officially expired on April 17, 2025. The Corporation has since been informed that the distribution agreement for Pantoprazole Magnesium — the second product licensed from the same partner, representing approximately 10.6% of revenues for the fiscal year ended July 31, 2024, and 4.2% for the nine-month period ended April 30, 2025 — will terminate on April 23, 2026. The Corporation will continue to market and sell Pantoprazole Magnesium until that date, maintaining revenue contributions in the interim. At the same time, management is carefully evaluating strategic options for this business unit.

Private Placement

On August 7, 2025, the Corporation announced the closing of a non-brokered private placement for aggregate gross proceeds of $2,272,999.85. The Corporation wishes to modify its press release to correct the information previously disclosed regarding the total gross proceeds, which was stated as $2,272,999.85, to reflect that it should have been $2,362,999.80 (the “Offering”). The Offering consisted of the issuance of 15,753,332 units (instead of the 15,153,332 units initially disclosed) of the Corporation (the “Units”) at a price of $0.15 per Unit. Each Unit is comprised of one common share of the Corporation (the “Shares”) and one Share purchase warrant (a “Warrant”). Each Warrant entitles the holder to purchase one Share at an exercise price of $0.20 per Share for a period of 24 months from the date of issuance. All other information remains unchanged.

About Devonian

Devonian Health Group Inc. is a clinical stage pharmaceutical company specializing in the development of drugs for various auto-immune inflammatory conditions with novel therapeutic approaches to targeting unmet medical needs. Devonian’s core strategy is to develop prescription drugs for the treatment of inflammatory autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian’s focus is further supported by a U.S. Food and Drug Administration set of regulatory guidelines favoring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines.

Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian also owns a commercialization subsidiary, Altius Healthcare Inc., focused on selling prescription pharmaceutical products in Canada, under license from brand name pharmaceutical companies.

Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Québec, Canada where it owns a state-of-the art extraction facility with full traceability ‘from the seed to the pill’. Devonian is traded publicly on the TSX Venture Exchange (the “Exchange”) (TSXV: GSD) and on OTCQB exchange (OTCQB: DVHGF).

For more information, visit www.groupedevonian.com.

Cautionary Note Regarding Forward-Looking Statements

All statements, other than statements of historical fact, contained in this press release including, but not limited to those relating to the intended use of proceeds, the final approval of the TSX Venture Exchange in connection with the Offering and generally, the above “About Devonian” paragraph, which essentially describes the Corporation’s outlook, constitute “forward-looking information” or “forward-looking statements” within the meaning of certain securities laws, and are based on expectations, estimates and projections as of the time of this press release.

Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Corporation as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect. Many of these uncertainties and contingencies can directly or indirectly affect, and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that these assumptions will prove to be correct and there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections and other forward-looking statements will not be achieved or that assumptions do not reflect future experience. Forward-looking statements are provided for the purpose of providing information about management’s expectations and plans relating to the future. Readers are cautioned not to place undue reliance on these forward-looking statements as a number of important risk factors and future events could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates, assumptions and intentions expressed in such forward-looking statements. All of the forward-looking statements made in this press release are qualified by these cautionary statements and those made in our other filings with the applicable securities regulators of Canada. The Corporation disclaims any intention or obligation to update or revise any forward-looking statements or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act“) and may not be offered or sold to, or for the account or benefit of, persons in the United States or U.S. persons absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws. “United States” and “U.S. person” are as defined in Regulation S under the U.S. Securities Act.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CONTACT:

Dr. André P. Boulet, PhD
Chairman and Chief Executive Officer
Devonian Health Group inc.
Telephone: 1 (450) 979-2916
E-mail: investors@groupedevonian.com

The post Devonian Provides Corporate Update and Additional Information Regarding its Previously Announced Private Placement appeared first on DEVONIAN HEALTH GROUP INC..

Devonian Announces Closing of a Private Placement of Units

Not for distribution to United States newswire services or for dissemination in the United States

QUEBEC, August 7, 2025 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to inflammatory diseases, announces that it has closed its non-brokered private placement for aggregate gross proceeds of $2,272,999.85 (the “Offering”). The Offering consisted of the issuance of 15,153,332 units of the Corporation (the “Units”) at a price of $0.15 per Unit. Each Unit consists of one subordinate voting share of the Corporation (a “Share”) and one Share purchase warrant (a “Warrant”). Each Warrant entitles the holder thereof to purchase one Share at an exercise price of $0.20 per Share for a period of 24 months from the date of issuance thereof.

The proceeds of the Offering will primarily be used to finance working capital related to the Corporation’s corporate overhead and research and development activities.

A total of $2,700.00 cash finder’s fees were paid in connection with this Offering. The Shares and the Warrants issued pursuant to this Offering are subject to a restricted hold period of four months and one day, ending on December 8, 2025, under applicable Canadian securities laws. The Offering remains subject to the final approval of the TSX Venture Exchange.

About Devonian

Devonian Health Group Inc. is a clinical stage pharmaceutical company specializing in the development of drugs for various auto-immune inflammatory conditions with novel therapeutic approaches to targeting unmet medical needs. Devonian’s core strategy is to develop prescription drugs for the treatment of inflammatory autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian’s focus is further supported by a U.S. Food and Drug Administration set of regulatory guidelines favoring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines.

Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian also owns a commercialization subsidiary, Altius Healthcare Inc., focused on selling prescription pharmaceutical products in Canada, under license from brand name pharmaceutical companies.

Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Québec, Canada where it owns a state-of-the art extraction facility with full traceability ‘from the seed to the pill’. Devonian is traded publicly on the TSX Venture Exchange (the “Exchange”) (TSXV: GSD) and on OTCQB exchange (OTCQB: DVHGF).

For more information, visit www.groupedevonian.com.

Cautionary Note Regarding Forward-Looking Statements

All statements, other than statements of historical fact, contained in this press release including, but not limited to those relating to the intended use of proceeds, the final approval of the TSX Venture Exchange in connection with the Offering and generally, the above “About Devonian” paragraph, which essentially describes the Corporation’s outlook, constitute “forward-looking information” or “forward-looking statements” within the meaning of certain securities laws, and are based on expectations, estimates and projections as of the time of this press release.

Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Corporation as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect. Many of these uncertainties and contingencies can directly or indirectly affect, and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that these assumptions will prove to be correct and there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections and other forward-looking statements will not be achieved or that assumptions do not reflect future experience. Forward-looking statements are provided for the purpose of providing information about management’s expectations and plans relating to the future. Readers are cautioned not to place undue reliance on these forward-looking statements as a number of important risk factors and future events could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates, assumptions and intentions expressed in such forward-looking statements. All of the forward-looking statements made in this press release are qualified by these cautionary statements and those made in our other filings with the applicable securities regulators of Canada. The Corporation disclaims any intention or obligation to update or revise any forward-looking statements or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) and may not be offered or sold to, or for the account or benefit of, persons in the United States or U.S. persons absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws. “United States” and “U.S. person” are as defined in Regulation S under the U.S. Securities Act.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CONTACT:

Dr. Andre P. Boulet, PhD
Chairman and Chief Executive Officer
Devonian Health Group inc.
Telephone: 1 (450) 979-2916
E-mail: investors@groupedevonian.com

The post Devonian Announces Closing of a Private Placement of Units appeared first on DEVONIAN HEALTH GROUP INC..

Devonian Health Group Reports Third Quarter 2025 Financial Results

• Third quarter revenues increased 36% compared to 3Q24
• Third quarter net loss of $0.032 per share

Québec, QUÉBEC, June 26, 2025 – Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), today announced financial results for its third quarter ended on April 30, 2025.

Management Comments

“The operating cash flows generated by Altius revenues continued to support the development progress of Thykamine™, our lead product candidate, While our distribution agreement for DEXLANSOPRAZOLE has now ended, our liquidity has enabled us to continue creating value by advancing our Thykamine™ development program,” said Dr André Boulet, Chief Executive Officer of the Company.

Business Highlights

• Completed preclinical studies designed to demonstrate new potential applications of Thykamine™ across even more inflammatory diseases, including MASH and fibrosis.
• Appointment of Dr Andre Boulet as Chief Executive Officer.
• Appointment of Luc Gregoire as Executive Vice-President Strategy.

Financial Highlights

• Distribution revenue for the third quarter was $7.36 million driven by DEXLANSOPRAZOLE revenues which launched in early 2024 but has now ended as of April 2025.
• The Company recorded during the quarter a non-cash impairment loss of $4.84 million against goodwill and intangible assets associated with the expiration of the Dexlansoprazole agreement which represented 95% of revenue in the current fiscal year to date.
• Net loss for the quarter was $4.8 million, or $0.032 per share, entirely attributable to the $4.84 million non-cash impairment loss mentioned above.

To consult the Interim Consolidated Financial Statements for the three and nine month periods ended April 30, 2025 and 2024, please click on the following link: https://groupedevonian.com/investor-center/financial-reports/.

About Devonian

Devonian Health Group is a clinical stage pharmaceutical company specializing in the development of drugs for various auto-immune inflammatory conditions with novel therapeutic approaches to targeting unmet medical needs. Devonian’s core strategy is to develop prescription drugs for the treatment of inflammatory autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian’s focus is further supported by a US FDA set of regulatory guidelines favoring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines.

Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian also owns a commercialization subsidiary, Altius Healthcare Inc., focused on selling prescription pharmaceutical products in Canada, under license from brand name pharmaceutical companies.

Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Québec, Canada where it owns a state-of-the art extraction facility with full traceability ‘from the seed to the pill’. Devonian is traded publicly on the TSX Venture Exchange (the “Exchange”) (TSXV: GSD) and on OTCQB exchange (OTCQB: DVHGF).

For more information, visit www.groupedevonian.com.

About Altius

Altius is a generic pharmaceutical distribution division with a primary focus of acquiring and in-licensing safe and innovative medicines and healthcare products designed to help people of all ages live healthier lives. Altius then leverages its expertise in the commercialization activities required to successfully launch and distribute these medicines in Canada.

Cautionary Note Regarding Forward-Looking Statements

All statements, other than statements of historical fact, contained in this press release including, but not limited to those relating, the final approval of the Exchange for the Option Plan and the Right Plan, the completion of the Share consolidation, if any, the approval of the Exchange regarding the Share consolidation, the final chosen consolidation ratio, the anticipated benefits of completing the Share consolidation, and, generally the above “About Devonian” paragraph, which essentially describes the Corporation’s outlook, constitute “forward-looking information” or “forward-looking statements” within the meaning of certain securities laws, and are based on expectations, estimates and projections as of the time of this press release.

Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Corporation as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect. Many of these uncertainties and contingencies can directly or indirectly affect, and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that these assumptions will prove to be correct and there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections and other forward-looking statements will not be achieved or that assumptions do not reflect future experience. Forward-looking statements are provided for the purpose of providing information about management’s expectations and plans relating to the future. Readers are cautioned not to place undue reliance on these forward-looking statements as a number of important risk factors and future events could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates, assumptions and intentions expressed in such forward-looking statements. All of the forward-looking statements made in this press release are qualified by these cautionary statements and those made in our other filings with the applicable securities regulators of Canada. The Corporation disclaims any intention or obligation to update or revise any forward-looking statements or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law.

Neither the Exchange nor its Regulation Services Provider (as that term is defined in policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

CONTACT:

Devonian Health Group Inc.

Dr. Andre Boulet, CEO
Ms Viktoria Krasteva, CFO

Telephone: 1 (450) 979-2916
E-mail: investors@groupedevonian.com

The post Devonian Health Group Reports Third Quarter 2025 Financial Results appeared first on DEVONIAN HEALTH GROUP INC..

QUÉBEC, Québec, June 9, 2025 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to inflammatory diseases, today announced the appointment of Dr. André Boulet as Chief Executive Officer of the Corporation, replacing Mr. Luc Gregoire who will continue in the new role of Executive Vice-President Strategy of the Corporation, effective June 9, 2025.

“As we enter a new phase of development, we are fortunate to retain Luc’s deep strategic insight and leadership in a role focused on long-term planning and innovation. As Executive Vice President of Strategy, he will continue to drive key initiatives, ensuring continuity and alignment with our mission while supporting the executive team through this important transition,” stated Dr. Boulet, President & CEO of the Company.

“I look forward to continuing to advise the executive team and help garner support from external stakeholders, as the Company sharpens its focus on its high potential anti-inflammatory clinical programs,” said Luc Gregoire.

The Corporation also announced that its board of directors has approved the grant of options to purchase common shares of the Corporation (the “Stock Options”) primarily for a director of the Corporation and the Chief Financial Officer, both of whom joined the organization in the past few months. The Stock Options were granted at an exercise price of $0.15 for a period of 10 years from the date of grant, which ends on June 9, 2035. An aggregate of 438,596 Stock Options was granted to a director of the Corporation and an aggregate of 850,000 Stock Options was granted to employees of the Corporation. 50.33% of these Stock Options are exercisable immediately,12.42 % shall vest upon the date that is 12 months from the date of issuance; 12.42 % shall vest upon the date that is 24 months from the date of issuance 12.42 % shall vest upon the date that is 36 months from the date of issuance and the remaining 12,42% shall vest upon the date that is 48 months from the date of issuance.

About Devonian

Devonian Health Group Inc. is a clinical stage pharmaceutical company specializing in the development of drugs for various auto-immune inflammatory conditions with novel therapeutic approaches to targeting unmet medical needs. Devonian’s core strategy is to develop prescription drugs for the treatment of inflammatory autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian’s focus is further supported by a U.S. Food and Drug Administration set of regulatory guidelines favoring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines.

Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian also owns a commercialization subsidiary, Altius Healthcare Inc., focused on selling prescription pharmaceutical products in Canada, under license from brand name pharmaceutical companies.

Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Québec, Canada where it owns a state-of-the art extraction facility with full traceability ‘from the seed to the pill’. Devonian is traded publicly on the TSX Venture Exchange (the “Exchange”) (TSXV: GSD) and on OTCQB exchange (OTCQB: DVHGF).

For more information, visit www.groupedevonian.com.

Cautionary Note Regarding Forward-Looking Statements

All statements, other than statements of historical fact, contained in this press release including, but not limited to those relating, the final approval of the Exchange for the Option Plan and the Right Plan, the completion of the Share consolidation, if any, the approval of the Exchange regarding the Share consolidation, the final chosen consolidation ratio, the anticipated benefits of completing the Share consolidation, and, generally the above “About Devonian” paragraph, which essentially describes the Corporation’s outlook, constitute “forward-looking information” or “forward-looking statements” within the meaning of certain securities laws, and are based on expectations, estimates and projections as of the time of this press release.

Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Corporation as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect. Many of these uncertainties and contingencies can directly or indirectly affect, and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that these assumptions will prove to be correct and there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections and other forward-looking statements will not be achieved or that assumptions do not reflect future experience. Forward-looking statements are provided for the purpose of providing information about management’s expectations and plans relating to the future. Readers are cautioned not to place undue reliance on these forward-looking statements as a number of important risk factors and future events could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates, assumptions and intentions expressed in such forward-looking statements. All of the forward-looking statements made in this press release are qualified by these cautionary statements and those made in our other filings with the applicable securities regulators of Canada. The Corporation disclaims any intention or obligation to update or revise any forward-looking statements or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law.

Neither the Exchange nor its Regulation Services Provider (as that term is defined in policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

CONTACT:

Devonian Health Group Inc.
Dr. André Boulet
Chief Executive Officer
Telephone: 1 (514) 248-7509
E-mail: investors@groupedevonian.com

The post DEVONIAN APPOINTS NEW OFFICERS AND ANNOUNCES GRANT OF STOCK OPTIONS appeared first on DEVONIAN HEALTH GROUP INC..

QUÉBEC, April 28, 2025 – Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), announced that the TSX Venture Exchange (the “Exchange”) has approved its application for reinstatement of trading of the Company’s common shares on the Exchange effective April 30, 2025. This follows the successful resolution of the Failure-to-File Cease Trade Order (the “FFCTO”) issued by the Autorité des marchés financiers (the “AMF”) on April 7, 2025, and revoked on April 16, 2025.

The FFCTO was issued as a result of the delay in filing the Company’s interim financial statements for the fiscal quarter ended January 31, 2025, its management’s discussion and analysis for the fiscal quarter ended January 31, 2025, and related filings (collectively, the “Required Interim Filings”). The Company filed the Required Interim Filings on April 15, 2025, upon which to the AMF had  the FFCTO revoked on which the the Exchange allowed the Company’s common shares to resume trading.

The Company acknowledges and appreciates the patience of its shareholders and stakeholders during this process and reaffirms its commitment to adhering to high standards of compliance and corporate governance.

About Devonian

Devonian Health Group Inc. is a clinical stage pharmaceutical company specializing in the development of drugs for various auto-immune inflammatory conditions with novel therapeutic approaches to targeting unmet medical needs. Devonian’s core strategy is to develop prescription drugs for the treatment of inflammatory autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian’s focus is further supported by a U.S. Food and Drug Administration set of regulatory guidelines favoring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines.

Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian also owns a commercialization subsidiary, Altius Healthcare Inc., focused on selling prescription pharmaceutical products in Canada, under license from brand name pharmaceutical companies.

Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Québec, Canada where it owns a state-of-the art extraction facility with full traceability ‘from the seed to the pill’. Devonian is traded publicly on the TSX Venture Exchange (the “Exchange”) (TSXV: GSD) and on OTCQB exchange (OTCQB: DVHGF).

For more information, visit www.groupedevonian.com

Cautionary Note Regarding Forward-Looking Statements

All statements, other than statements of historical fact, contained in this press release including, but not limited to those relating, the final approval of the Exchange for the Option Plan and the Right Plan, the completion of the Share consolidation, if any, the approval of the Exchange regarding the Share consolidation, the final chosen consolidation ratio, the anticipated benefits of completing the Share consolidation, and, generally the above “About Devonian” paragraph, which essentially describes the Corporation’s outlook, constitute “forward-looking information” or “forward-looking statements” within the meaning of certain securities laws, and are based on expectations, estimates and projections as of the time of this press release.

Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Corporation as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect. Many of these uncertainties and contingencies can directly or indirectly affect, and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that these assumptions will prove to be correct and there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections and other forward-looking statements will not be achieved or that assumptions do not reflect future experience. Forward-looking statements are provided for the purpose of providing information about management’s expectations and plans relating to the future. Readers are cautioned not to place undue reliance on these forward-looking statements as a number of important risk factors and future events could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates, assumptions and intentions expressed in such forward-looking statements. All of the forward-looking statements made in this press release are qualified by these cautionary statements and those made in our other filings with the applicable securities regulators of Canada. The Corporation disclaims any intention or obligation to update or revise any forward-looking statements or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law.

Neither the Exchange nor its Regulation Services Provider (as that term is defined in policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

CONTACT:

Devonian Health Group Inc.
Mr. Luc Grégoire
President and Chief Executive Officer
Dr. André Boulet
Chairman, Chief Operating Officer and Chief Scientific Officer

Telephone: 1 (450) 979-2916
E-mail: investors@groupedevonian.com

The post Devonian Health Group Announces Reinstatement of Quotation on the TSXV appeared first on DEVONIAN HEALTH GROUP INC..